Rosiglitazone may cut diabetic retinopathy risk
Rosiglitazone may reduce the risk of developing proliferative diabetic retinopathy and reduced visual acuity, a US study shows.
Researchers compared medical records from 124 patients who were treated with rosiglitazone and 158 who were treated for diabetes but did not take the drug. At the start of the study, 6.4% in the rosiglitazone group and 9.3% of controls had severe non-proliferative diabetic retinopathy.
Among those, only 7.7% of those on rosiglitazone had progressed to proliferative disease after one year compared with 29.2% of controls – with the differential maintained after a further two years of follow-up.
Arch Ophthalmol 2008;126:793-99